Nonalcoholic fatty liver disease and diabetes

Part II: Treatment

Kyung Soo Kim, byungwan lee, Yong Jin Kim, Dae Ho Lee, Bong Soo Cha, Cheol Young Park

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.

Original languageEnglish
Pages (from-to)127-143
Number of pages17
JournalDiabetes and Metabolism Journal
Volume43
Issue number2
DOIs
Publication statusPublished - 2019 Apr 1

Fingerprint

pioglitazone
Weight Loss
Therapeutics
Pharmaceutical Preparations
Non-alcoholic Fatty Liver Disease
Life Style
Pharmacology

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

Kim, Kyung Soo ; lee, byungwan ; Kim, Yong Jin ; Lee, Dae Ho ; Cha, Bong Soo ; Park, Cheol Young. / Nonalcoholic fatty liver disease and diabetes : Part II: Treatment. In: Diabetes and Metabolism Journal. 2019 ; Vol. 43, No. 2. pp. 127-143.
@article{b22443c224124ab79e92c7177993bed6,
title = "Nonalcoholic fatty liver disease and diabetes: Part II: Treatment",
abstract = "Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.",
author = "Kim, {Kyung Soo} and byungwan lee and Kim, {Yong Jin} and Lee, {Dae Ho} and Cha, {Bong Soo} and Park, {Cheol Young}",
year = "2019",
month = "4",
day = "1",
doi = "10.4093/dmj.2019.0034",
language = "English",
volume = "43",
pages = "127--143",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "2",

}

Nonalcoholic fatty liver disease and diabetes : Part II: Treatment. / Kim, Kyung Soo; lee, byungwan; Kim, Yong Jin; Lee, Dae Ho; Cha, Bong Soo; Park, Cheol Young.

In: Diabetes and Metabolism Journal, Vol. 43, No. 2, 01.04.2019, p. 127-143.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Nonalcoholic fatty liver disease and diabetes

T2 - Part II: Treatment

AU - Kim, Kyung Soo

AU - lee, byungwan

AU - Kim, Yong Jin

AU - Lee, Dae Ho

AU - Cha, Bong Soo

AU - Park, Cheol Young

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.

AB - Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85065721050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065721050&partnerID=8YFLogxK

U2 - 10.4093/dmj.2019.0034

DO - 10.4093/dmj.2019.0034

M3 - Review article

VL - 43

SP - 127

EP - 143

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 2

ER -